Targeting microbiota to increase cancer immunotherapy efficacy

Dr Bertrand RoutyDr. Bertrand Routy, from the University of Montreal Hospital, Canada will be discussing his most recent findings on ''Targeting microbiota to increase cancer immunotherapy efficacy'

Dr. Routy explains that immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized the treatment for several cancers, including the most common lung cancer type, non-small cell lung cancer (NSCLC). However, only a minority of patients experience a long-lasting response and resistance to ICI treatment is common.

Recent efforts to increase the benefits of ICI to a greater majority of patients have involved strategies that target the gut microbiome to enhance the number of immune cells and their activity within the tumors, which translates into better outcome.

Microbiome profiling and experiments in mouse models have identified specific bacterial species as biomarkers of ICI response and established the gut microbiome as a key mediator of the anti-tumor immunity influencing ICI efficacy. Shifting the microbiome toward a more diverse and beneficial bacterial composition has also shown potential as a therapeutic approach to circumvent ICI resistance and enhance the immune T cell activity that promotes an ICI response.

Join us for Targeting Microbiota 2022, this October- in Paris, to know more about the complex interaction between microbiota and cancer.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France



Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next